Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
RLMD Relmada Therapeutics
- 0.6471
- -0.0429-6.22%
Trading Apr 24 12:18 ET
21.48MMarket Cap-0.24P/E (TTM)
0.6660High0.5409Low3.55MVolume0.6194Open0.6900Pre Close2.18MTurnover11.61%Turnover RatioLossP/E (Static)33.19MShares4.470052wk High0.60P/B19.78MFloat Cap0.240452wk Low--Dividend TTM30.57MShs Float54.0000Historical High--Div YieldTTM18.13%Amplitude0.2404Historical Low0.6140Avg Price1Lot Size
Relmada Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Cash, cash equivalents and short term investments | -53.38%44.91M | -53.38%44.91M | -49.07%54.12M | -40.57%70.44M | -36.87%83.61M | -35.06%96.32M | -35.06%96.32M | -42.29%106.27M | -44.08%118.53M | -39.98%132.44M |
| -Cash and cash equivalents | -5.73%3.86M | -5.73%3.86M | -77.85%1.48M | -85.58%2.09M | -95.38%1.34M | -24.17%4.09M | -24.17%4.09M | -84.25%6.7M | -61.17%14.47M | -35.70%28.89M |
| -Short-term investments | -55.49%41.05M | -55.49%41.05M | -47.14%52.63M | -34.32%68.35M | -20.54%82.28M | -35.47%92.23M | -35.47%92.23M | -29.70%99.57M | -40.43%104.06M | -41.07%103.55M |
| Receivables | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | --0 |
| Prepaid assets | -25.20%886.46K | -25.20%886.46K | -44.08%1.58M | -84.53%537.52K | -75.65%752.33K | -70.63%1.19M | -70.63%1.19M | -4.05%2.83M | -0.26%3.47M | -69.05%3.09M |
| Other current assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -5.13%37 | ---- | ---- |
| Total current assets | -53.03%45.8M | -53.03%45.8M | -48.94%55.7M | -41.83%70.97M | -37.75%84.37M | -36.21%97.51M | -36.21%97.51M | -41.69%109.1M | -43.45%122M | -39.97%135.53M |
| Non current assets | ||||||||||
| Other non current assets | -49.04%21.98K | -49.04%21.98K | -53.95%21.98K | 55.03%53.63K | 23.66%43.13K | 23.66%43.13K | 23.66%43.13K | 196.46%47.72K | -1.84%34.59K | 23.26%34.88K |
| Total non current assets | -49.04%21.98K | -49.04%21.98K | -53.95%21.98K | 55.03%53.63K | 23.66%43.13K | 23.66%43.13K | 23.66%43.13K | 196.46%47.72K | -1.84%34.59K | 23.26%34.88K |
| Total assets | -53.03%45.82M | -53.03%45.82M | -48.95%55.72M | -41.80%71.03M | -37.74%84.41M | -36.20%97.55M | -36.20%97.55M | -41.67%109.15M | -43.44%122.04M | -39.96%135.57M |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Payables | 17.81%4.13M | 17.81%4.13M | -17.89%2.35M | -13.99%4.17M | 17.35%5.19M | -33.37%3.51M | -33.37%3.51M | -72.60%2.86M | -35.63%4.85M | -58.56%4.42M |
| -accounts payable | 17.81%4.13M | 17.81%4.13M | -17.89%2.35M | -13.99%4.17M | 17.35%5.19M | -33.37%3.51M | -33.37%3.51M | -72.60%2.86M | -35.63%4.85M | -58.56%4.42M |
| Current accrued expenses | -11.92%5.01M | -11.92%5.01M | 6.64%4.38M | -25.70%4.35M | 14.45%6.5M | -8.10%5.68M | -8.10%5.68M | -51.85%4.1M | -41.68%5.85M | 48.84%5.68M |
| Other current liabilities | 400.00%27 | 400.00%27 | 158.82%20 | ---20 | ---- | -121.95%-9 | -121.95%-9 | -383.33%-34 | ---- | ---- |
| Current liabilities | -15.61%10.29M | -15.61%10.29M | -3.98%8.09M | -10.89%9.54M | 22.43%12.36M | -2.20%12.19M | -2.20%12.19M | -59.46%8.42M | -43.44%10.7M | -34.47%10.1M |
| Non current liabilities | ||||||||||
| Employee benefits | --4.47K | --4.47K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Other non current liabilities | ---- | ---- | --12.56K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Total non current liabilities | --4.47K | --4.47K | --12.56K | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Total liabilities | -15.57%10.3M | -15.57%10.3M | -3.83%8.1M | -10.89%9.54M | 22.43%12.36M | -2.20%12.19M | -2.20%12.19M | -59.46%8.42M | -43.44%10.7M | -34.47%10.1M |
| Shareholders'equity | ||||||||||
| Share capital | 0.25%30.17K | 0.25%30.17K | 0.25%30.17K | 0.25%30.17K | 0.25%30.17K | 0.00%30.1K | 0.00%30.1K | 5.09%30.1K | 0.25%30.1K | 2.37%30.1K |
| -common stock | 0.25%30.17K | 0.25%30.17K | 0.25%30.17K | 0.25%30.17K | 0.25%30.17K | 0.00%30.1K | 0.00%30.1K | 5.09%30.1K | 0.25%30.1K | 2.37%30.1K |
| -Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Retained earnings | -14.26%-640.88M | -14.26%-640.88M | -16.14%-622.22M | -16.89%-600.5M | -19.31%-582.73M | -21.38%-560.9M | -21.38%-560.9M | -26.30%-535.74M | -33.53%-513.74M | -41.65%-488.43M |
| Paid-in capital | 4.66%676.37M | 4.66%676.37M | 5.25%669.82M | 5.91%661.96M | 6.66%654.75M | 7.26%646.23M | 7.26%646.23M | 7.78%636.43M | 7.47%625.04M | 10.57%613.87M |
| Total stockholders'equity | -58.38%35.52M | -58.38%35.52M | -52.72%47.63M | -44.77%61.49M | -42.58%72.05M | -39.22%85.36M | -39.22%85.36M | -39.45%100.73M | -43.44%111.34M | -40.37%125.47M |
| Total equity | -58.38%35.52M | -58.38%35.52M | -52.72%47.63M | -44.77%61.49M | -42.58%72.05M | -39.22%85.36M | -39.22%85.36M | -39.45%100.73M | -43.44%111.34M | -40.37%125.47M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀